Related Experiment Videos
Relationship between PAF-acether and thromboxane A2 biosynthesis in endotoxin-induced intestinal damage in the rat
N K Boughton-Smith1, I Hutcheson, B J Whittle
1Department of Pharmacology, Wellcome Research Laboratories, Beckenham, Kent, England, United Kingdom.
Abstract:
PAF-receptor antagonists are known to inhibit gastrointestinal damage induced by endotoxin. In the present study, the interaction between the biosynthesis of PAF and thromboxane (TX) A2, as putative mediators of the acute intestinal damage induced by endotoxin, has been investigated in the anaesthetised rat. Bolus intravenous administration of lipopolysaccharide from E. coli (5-50 mg/kg) induced dose-related jejunal damage, assessed using both macroscopic and histological techniques. This damage was accompanied by significant increases in the jejunal formation of PAF determined by bioassay, and of TXB2, determined by radioimmunoassay. Pretreatment with the structurally-unrelated thromboxane synthase inhibitors, 1-benzyl imidazole (10-50 mg/kg) or OKY 1581 (25 mg/kg) substantially reduced both jejunal damage and TXB2 formation, but did not inhibit PAF formation. Likewise, pretreatment with indomethacin (5 mg/kg) or BW 755C (50 mg/kg) reduced jejunal damage and TXB2 formation but did not affect PAF formation. Pretreatment (2h) with dexamethasone (4 mg/kg) reduced jejunal damage and the formation of both TXB2 and PAF. Intravenous infusion of PAF (100 ng/kg/min for 10 min) induced jejunal damage and significantly increased the formation of TXB2, whereas non-specific jejunal damage induced by oral administration of ethanol did not augment PAF formation. The present findings that inhibition of jejunal thromboxane formation is associated with a substantial reduction in jejunal damage, with no corresponding inhibition in PAF formation, therefore suggests a complex interaction or sequential release of these tissue destructive mediators underlying the intestinal damage induced by endotoxin.
Insights
Endotoxin-induced intestinal damage in rats involves platelet-activating factor (PAF) and thromboxane A2 (TXA2). Inhibiting TXA2 formation significantly reduced damage, suggesting a key role for TXA2 in this process.
Area of Science:
- Gastroenterology
- Pharmacology
- Immunology
Background:
- Platelet-activating factor (PAF) receptor antagonists inhibit endotoxin-induced gastrointestinal damage.
- Acute intestinal damage from endotoxin may involve PAF and thromboxane (TX) A2 as mediators.
Purpose of the Study:
- To investigate the interaction between PAF biosynthesis and thromboxane A2 in endotoxin-induced acute intestinal damage in rats.
Main Methods:
- Administered lipopolysaccharide (LPS) to anesthetized rats to induce dose-related jejunal damage.
- Assessed jejunal damage macroscopically and histologically.
- Measured jejunal formation of PAF and TXB2 using bioassay and radioimmunoassay, respectively.
- Utilized thromboxane synthase inhibitors, indomethacin, BW 755C, and dexamethasone as pretreatments.
Main Results:
- LPS induced dose-related jejunal damage, increasing PAF and TXB2 formation.
- Thromboxane synthase inhibitors and other agents reduced jejunal damage and TXB2 levels, but not PAF formation.
- Dexamethasone reduced both jejunal damage and the formation of TXB2 and PAF.
- PAF infusion caused jejunal damage and increased TXB2 formation.
Conclusions:
- Inhibition of jejunal thromboxane formation significantly reduces endotoxin-induced intestinal damage.
- Findings suggest a complex interaction or sequential release of PAF and TXA2 in endotoxin-induced intestinal damage.